{"id":411135,"date":"2021-01-08T09:03:07","date_gmt":"2021-01-08T14:03:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411135"},"modified":"2021-01-08T09:03:07","modified_gmt":"2021-01-08T14:03:07","slug":"data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/","title":{"rendered":"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>PHILADELPHIA, PA, Jan.  08, 2021  (GLOBE NEWSWIRE) &#8212; <\/strong>Vallon Pharmaceuticals Inc., (\u201cVallon\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on the development of novel drugs for CNS disorders, today announced data from two studies evaluating its investigational new drug, <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nMg-vrZVr9ICBBtQFcFni7ED_W2m0zxmwqge72PbmLjoTbFhWcgEkDplcbSAkulzUEYA4PCq1CPl7EkjJ_3BF6HQ3wqQWoUnJ64V0xeOEwfowClg80owqL43CMQ8BBUvWZTMGj7uQWWHLwg3bhUOpQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>A<\/u><u>buse <\/u><u>D<\/u><u>eterrent <\/u><u>A<\/u><u>mphetamine <\/u><u>I<\/u><u>mmediate <\/u><u>R<\/u><u>elease<\/u><\/a><\/strong> (ADAIR), have been selected for a symposia presentation at the virtual <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Swa2FMcDulZGm89UkiVipnrpPUktK32vmPZBU0XXuSoBgnzhq4NnbUwhWGUtS4SJ9_C7hj2JLIoG16NXbqH2a9kGkyASSJuP81rpIzq54dtSMVDI2-mpO8FmYusNPuXi1D3MicuHoh5Mdjz7XYp6NThvuKVHOkz8G8Sv_1BAE8gnsr0ftCIHgjb07mDkUE1OLek-Rv3Uao_iJnLoqHZ3Pg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>2021 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting<\/u><\/a> being held January 15-17, 2021.<\/p>\n<p align=\"justify\">Summarized below is the symposia abstract title selected for presentation. The APSARD Annual Meeting agenda and abstracts are available online at the conference <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oW7wZOabEge8sv43l4soTWpgSFfV65EaMMKpTTQi8Rxcbqzgw06NBxrLFRVXC6HZKE6sKJeBIKJNPrnCDCroVVGBbMhfXD4vOLT-oJ3dfRja-ousGhcUxPlbGACRRIgN\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>website<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Symposia Session<\/strong>: Novel Pharmacology and Technology Approaches to the Non-Medical Use of Stimulants<\/p>\n<p align=\"justify\">\n        <strong>Date:<\/strong> Friday, January 15, 2021 at 4:05 PM<\/p>\n<p align=\"justify\">\n        <strong>Presenter:<\/strong> Timothy Wilens, M.D., chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital<\/p>\n<p align=\"justify\">\n        <strong>Abstract Title: <\/strong><br \/>\n        <em>Pharmacokinetic and Pharmacodynamic Studies of an Abuse Deterrent Formulation of Dextroamphetamine<\/em>\n      <\/p>\n<p>\n        <strong>About ADAIR<\/strong>\n      <\/p>\n<p align=\"justify\">ADAIR (<strong>A<\/strong>buse\u00a0<strong>D<\/strong>eterrent\u00a0<strong>A<\/strong>mphetamine\u00a0<strong>I<\/strong>mmediate\u00a0<strong>R<\/strong>elease) is an investigational new drug; a novel, patented formulation of dextroamphetamine designed to deter attempts to crush and snort it or take it by other non-oral routes that can produce a greater \u201chigh.\u201d Dextroamphetamine has been used clinically for more than fifty years. It is the same active ingredient used in FDA-approved products, such as Adderall<sup>\u00ae<\/sup>, Dexedrine<sup>\u00ae<\/sup>, and Vyvanse<sup>\u00ae<\/sup>. ADAIR is not approved by the FDA.<\/p>\n<p>\n        <strong>About Vallon Pharmaceuticals Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Vallon Pharmaceuticals Inc. is a private, clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company\u2019s lead investigational product candidate, ADAIR, is a novel formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.<\/p>\n<p align=\"justify\">For more information about the company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gQR0oKFL-jxbj5KGfGySE1tMxgSb5tvP1QaWZtm8cFkNL3l7MZnvykzviywabArs-p7QIptufRnKM5_hQYQq-OJ6vDQCfRA8MgtQUO2z1q4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.vallon-pharma.com<\/u><\/a> or connect with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3YczRJv6ELsN36anGphKekxq05QzpKAhJG5IXQZMtE-pfsO9gb21ejjk3_AiGwzTcl7SmEKlONMZDcJGSE9ZH29rRqx2pkd-N7bbGktpa56OGz3lbD7rsmfsxRuLM2fT\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>LinkedIn<\/u><\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wv4KvtJkCW4-PVv8c6IcMUqkx8NY-0cLw9LxVNeTEkwR0OEQk3CtOv1LgKTVxh5RlAagJKg3PssbUtJbIHuBZw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Twitter<\/u><\/a>.<\/p>\n<p align=\"justify\">*Adderall, Dexedrine, and Vyvanse are registered trademarks of their respective companies.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas<br \/>(833) 475-8247<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kPGCbAW9cZfmT5YikRSfBxHIytfMvnKa--guR9FFFEMbBIWMkJqGnnVGunyFIlLvDbKXA_ASYsFcXhrOeqMLWg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>vallon@jtcir.com<\/u><\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/a21e5d70-9f99-4945-858d-0cc294718de2\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, PA, Jan. 08, 2021 (GLOBE NEWSWIRE) &#8212; Vallon Pharmaceuticals Inc., (\u201cVallon\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on the development of novel drugs for CNS disorders, today announced data from two studies evaluating its investigational new drug, Abuse Deterrent Amphetamine Immediate Release (ADAIR), have been selected for a symposia presentation at the virtual 2021 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting being held January 15-17, 2021. Summarized below is the symposia abstract title selected for presentation. The APSARD Annual Meeting agenda and abstracts are available online at the conference website. Symposia Session: Novel Pharmacology and Technology Approaches to the Non-Medical Use of Stimulants Date: Friday, January 15, 2021 at 4:05 PM Presenter: Timothy Wilens, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411135","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, PA, Jan. 08, 2021 (GLOBE NEWSWIRE) &#8212; Vallon Pharmaceuticals Inc., (\u201cVallon\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on the development of novel drugs for CNS disorders, today announced data from two studies evaluating its investigational new drug, Abuse Deterrent Amphetamine Immediate Release (ADAIR), have been selected for a symposia presentation at the virtual 2021 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting being held January 15-17, 2021. Summarized below is the symposia abstract title selected for presentation. The APSARD Annual Meeting agenda and abstracts are available online at the conference website. Symposia Session: Novel Pharmacology and Technology Approaches to the Non-Medical Use of Stimulants Date: Friday, January 15, 2021 at 4:05 PM Presenter: Timothy Wilens, &hellip; Continue reading &quot;Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-08T14:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting\",\"datePublished\":\"2021-01-08T14:03:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/\"},\"wordCount\":345,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/\",\"name\":\"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA==\",\"datePublished\":\"2021-01-08T14:03:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting - Market Newsdesk","og_description":"PHILADELPHIA, PA, Jan. 08, 2021 (GLOBE NEWSWIRE) &#8212; Vallon Pharmaceuticals Inc., (\u201cVallon\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on the development of novel drugs for CNS disorders, today announced data from two studies evaluating its investigational new drug, Abuse Deterrent Amphetamine Immediate Release (ADAIR), have been selected for a symposia presentation at the virtual 2021 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting being held January 15-17, 2021. Summarized below is the symposia abstract title selected for presentation. The APSARD Annual Meeting agenda and abstracts are available online at the conference website. Symposia Session: Novel Pharmacology and Technology Approaches to the Non-Medical Use of Stimulants Date: Friday, January 15, 2021 at 4:05 PM Presenter: Timothy Wilens, &hellip; Continue reading \"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-08T14:03:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting","datePublished":"2021-01-08T14:03:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/"},"wordCount":345,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/","name":"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA==","datePublished":"2021-01-08T14:03:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ0NCMzOTA5NTc0IzUwMDA3NTQ4OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-vallon-pharmaceuticals-adair-selected-for-symposia-presentation-at-the-virtual-2021-apsard-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Data from Vallon Pharmaceuticals\u2019 ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411135"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411135\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}